Forsta AP Fonden Purchases 3,900 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Forsta AP Fonden raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 7.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 54,800 shares of the biopharmaceutical company's stock after acquiring an additional 3,900 shares during the quarter. Forsta AP Fonden's holdings in Alnylam Pharmaceuticals were worth $12,895,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in ALNY. Huntington National Bank lifted its position in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 45 shares in the last quarter. Hollencrest Capital Management acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $29,000. R Squared Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $33,000. Washington Trust Advisors Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $42,000. Finally, True Wealth Design LLC raised its position in Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 153 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Up 1.0 %

Alnylam Pharmaceuticals stock traded up $2.63 during midday trading on Thursday, reaching $276.62. The stock had a trading volume of 126,418 shares, compared to its average volume of 666,812. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The firm's fifty day simple moving average is $249.42 and its 200-day simple moving average is $260.65. The stock has a market capitalization of $35.68 billion, a P/E ratio of -105.41 and a beta of 0.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same period last year, the firm earned $1.15 EPS. The company's revenue was down 33.3% compared to the same quarter last year. As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 52,592 shares of the company's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. This represents a 81.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the transaction, the executive vice president now owns 13,191 shares of the company's stock, valued at $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 73,964 shares of company stock worth $20,622,925 in the last three months. Insiders own 1.50% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Royal Bank of Canada reissued an "outperform" rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, January 21st. Piper Sandler reaffirmed an "overweight" rating and issued a $296.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Needham & Company LLC reissued a "buy" rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Finally, Barclays raised their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an "overweight" rating in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $298.61.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.